← boothcheck

Is CME overvalued?

boothcheck doesn't label CME overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, CME is priced for growth of +5.4%, and an operating margin near 20.8% versus the 66.9% it earns today. The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price. The more the price assumes beyond what CME GROUP INC. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from CME GROUP INC.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth+5.4%
For about
Margin needed20.8%
Margin today66.9%
Price vs asset value1.76x
Price vs earnings power2.25x
Price vs peer multiples1.24x
Price vs forward growth0.90x
Read the full CME report →
Get boothcheck's read on what CME's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.